We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fewer Regulatory Barriers in Europe Benefit Companion Diagnostics Sector

By LabMedica International staff writers
Posted on 01 Jul 2014
Print article
The growth in personalized medicine has led to increased interest in companion diagnostics (CDx) tests or tests that match the right therapy to the patient.

Over the past few years, market participants have been entering pharmaceutical and diagnostic partnerships in order to develop and commercialize CDx tests for drugs that already exist in the market. Currently, the oncology segment is the main focus in the CDx market, but it is envisioned that non-oncology segments—such as central nervous system, infectious disease, and cardiovascular conditions—will receive a great deal of attention in the years to come.

A new analysis from Frost & Sullivan (London, United Kingdom) finds that the CDx market earned revenues of USD 457 million in 2013 and estimates this to reach USD 1,295.1 million in 2018, at a compound annual growth rate of 23.2 %. The study covers the oncology areas such as breast cancer, colorectal cancer, and lung cancer panel segments and non-oncology areas such as infectious, CNS, and cardio vascular diseases for Western Europe, including the United Kingdom, Germany, Italy, France, Spain, Benelux, and Scandinavia.

Frost & Sullivan Healthcare senior industry analyst Divyaa Ravishankar commented, “Limited regulatory barriers for drug and diagnostic combination products, which the current in vitro diagnostic directive classifies under the low-risk category, are easing market access. As nearly all diagnostic tests in Europe belong to the low risk category, they are exempt from pre-market evaluation. As a result, manufacturers tend to self-assess conformity, self-certify CDx products, and CE mark them before sale in the European market. This laid-back process has resulted in a higher rate of approval of new CDx tests and products.”

Intense competition from laboratory-developed test (LDT) manufacturers—who offer tests through reference laboratories across Europe and the rest of the world—is hampering market growth. The entry of foreign LDT companies into the market through partnership with local companies, as well as the inclination of companies across Western Europe to promote the use of LDT over manufactured and approved CDx tests, are exacerbating the situation.

The variation in reimbursement policies across Western Europe is creating an unpredictable environment, adversely affecting the uptake of new CDx test technologies. Along with the lack of a robust coverage and payment process, this is denting the prospects of CDx manufacturers in the region.

Related Links:

Frost & Sullivan


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.